T3 levels in relation to prognostic factors in breast cancer: A population-based prospective cohort study

BMC Cancer

Volumn 14, Issue 1, 2014, Pages

  Tosovic, Ada ^a   Bondeson, Anne Greth ^a   Bondeson, Lennart ^b   Ericsson, Ulla Britt ^a   Manjer, Jonas ^a  

^a LUND UNIVERSITY HOSPITAL   (Sweden)

^b Department of Pathology University and Regional Laboratories Region Ska˚ne Lund University ^*  (Sweden)

Author keywords

Breast cancer; Prognostic factors; Triiodothyronine

Indexed keywords

ESTROGEN RECEPTOR; LIOTHYRONINE; PROGESTERONE RECEPTOR;

ADULT; ARTICLE; BREAST CANCER; CANCER PROGNOSIS; COHORT ANALYSIS; DISEASE ASSOCIATION; FEMALE; HUMAN; LIOTHYRONINE BLOOD LEVEL; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; POSTMENOPAUSE; PROSPECTIVE STUDY; TUMOR VOLUME; BLOOD; BREAST TUMOR; MIDDLE AGED; PATHOLOGY;

BREAST NEOPLASMS; FEMALE; HUMANS; LYMPHATIC METASTASIS; MIDDLE AGED; POSTMENOPAUSE; PROSPECTIVE STUDIES; RECEPTORS, ESTROGEN; RECEPTORS, PROGESTERONE; TRIIODOTHYRONINE;

EID: 84904525163     PISSN: None     EISSN: 14712407     Source Type: Journal    
DOI: 10.1186/1471-2407-14-536     Document Type: Article

References (33)

1. Sarlis NJ, Gourgiotis L, Pucino F, Tolis GJ. Lack of association between Hashimoto thyroiditis and breast cancer: a quantitative research synthesis. Hormones (Athens) 2002, 1:35-41.
2. Goldman MB. Thyroid diseases and breast cancer. Epidemiol Rev 1990, 12:16-28.
3. Smyth PP. The thyroid and breast cancer: a significant association?. Ann Med 1997, 29:189-191.
4. Fiore E, Giustarini E, Mammoli C, Fragomeni F, Campani D, Muller I, Pinchera A, Giani C. Favourable predictive value of thyroid autoimmunity in high aggressive breast cancer. J Endocrinol Invest 2007, 30:734-738.
5. Jiskra J, Barkmanova J, Limanova Z, La'nska V, Smutek D, Potlukova E, Antosova M. Thyroid autoimmunity occurs more frequently in women with breast cancer compared to women with colorectal cancer and controls but it has no impact on relapse-free and overall survival. Oncol Rep 2007, 18:1603-1611.
6. Farahati J, Roggenbuck D, Gilman E, Schu¨tte M, Jagminaite E, Seyed Zakavi R, Lo¨ning T, Heissen E. Anti-thyroid peroxidase antibodies are associated with the absence of distant metastases in patients with newly diagnosed breast cancer. Clin Chem Lab Med 2012, 50:709-714.
7. Cengiz O, Bozkurt B, Unal B, Yildirim O, Karabeyoglu M, Eroglu A, Kocer B, Ulas M. The relationship between prognostic factors of breast cancer and thyroid disorders in Turkish women. J Surg Oncol 2004, 87:19-25.
8. Lemaire M, Baugnet-Mahieu L. Thyroid function in women with breast cancer. Eur J Cancer Clin Oncol 1986, 22:301-307.
9. Tosovic A, Bondeson AG, Bondeson L, Ericsson UB, Malm J, Manjer J. Prospectively measured triiodothyronine levels are positively associated with breast cancer risk in postmenopausal women. Breast Cancer Res 2010, 12:R33.
10. Tosovic A, Bondenson AG, Bondeson L, Ericsson UB, Malm J, Manjer J. Prospectively measured thyroid hormones and thyroid peroxidase antibodies in relation to breast cancer risk. Int J Cancer 2012, 131:2126-2133.
11. Tosovic A, Bondenson AG, Bondeson L, Ericsson UB, Manjer J. Triiodothyronine levels in relation to mortality from breast cancer and all causes: a population-based prospective cohort study. Eur J Endocrinol 2013, 168:483-490.
12. Manjer J, Berglund G, Bondesson L, Garne JP, Janzon L, Malina J. Breast cancer incidence in relation to smoking cessation. Breast Cancer Res Treat 2000, 61:121-129.
13. Thorell JL, Larson SM. Radioimmunoassay and related techniques 1978, Methodology and Clinical Applications Saint Louis: Mosby.
14. Almquist M, Anagnostaki L, Bondeson L, Bondeson AG, Borgquist S, Landberg G, Malina J, Malm J, Manjer J. Serum calcium and tumour aggressiveness in breast cancer. Eur J Cancer Prev 2009, 18:354-360.
15. Elston CW, Ellis IO. Pathological prognostic factors in breast cancer. I. The value of histological grade in breast cancer: experience from a large study with long-term follow-up. Histopathology 1991, 19:403-410.
16. Michael B, Harvey S. Fast Facts - Breast Cancer 2002, Oxford: Health Press Limited.
17. Manjer J, Malina J, Berglund G, Bondeson L, Garne JP, Janzon L. Smoking associated with hormone receptor negative breast cancer. Int J Cancer 2001, 91:580-584.
18. Garne JP. Invasive breast cancer in Malmo 1961-1992 - an epidemiological study. A PhD Thesis 1996, Lund, Sweden: Department of Surgery, Lund University.
19. Russell W, Harrison RF, Smith N, Darzy K, Shalet S, Weetman AP, Ross RJ. Free triiodothyronine has a distinct circadian rhythm that is delayed but parallels thyrotropin levels. J Clin Endocrinol Metab 2008, 93:2300-2306.
20. Andersen S, Pedersen KM, Bruun NH, Laurberg P. Narrow individual variations in serum T(4) and T(3) in normal subjects: a clue to the understanding of subclinical thyroid disease. J Clin Endocrinol Metab 2002, 87:1068-1072.
21. Utiger RD. Estrogen, thyroxine binding in serum, and thyroxine therapy. N Engl J Med 2001, 344:1784.
22. Marti´nez-Iglesias O, Garci´a-Silva S, Regadera J, Aranda A. Hypothyroidism Enhances Tumour Invasiveness and Metastasis Development. PLoS One 2009, 4:e6428.
23. Economidou F, Douka E, Tzanela M, Nanas S, Kotanidou A. Thyroid function during critical illness. Hormones 2011, 10:117-124.
24. Saraiva PP, Figueiredo NB, Padovani CR, Bretani MM, Nogueira CR. Profile of thyroid hormones in breast cancer patients. Braz J Med Biol Res 2005, 38:761-765.
25. Dinda S, Sanchez A, Moudgil V. Estrogen-like effects of thyroid hormone on the regulation of tumor suppressor proteins, p53 and retinoblastoma, in breast cancer cells. Oncogene 2002, 21:761-768.
26. Conde I, Paniagua R, Zamora J, Blanquez MJ, Fraile B, Ruiz A, Arenas MI. Influence of thyroid hormone receptors on breast cancer cell proliferation. Ann Oncol 2006, 17:60-64.
27. Nogueira CR, Brentani MM. Triiodothyronine mimics the effects of estrogen in breast cancer cell lines. J Steroid Biochem Mol Biol 1996, 59:271-279.
28. Hall LC, Salazar EP, Kane SR, Liu N. Effects of thyroid hormones on human breast cancer cell proliferation. J Steroid Biochem Mol Biol 2008, 109:57-66.
29. Silva JM, Dominguez G, Gonza´lez-Sancho JM, Garcia JM, Silva J, Garcia-Andrade C, Navarro A, Muñoz A, Bonilla F. Expression of thyroid hormone receptor/erbA genes is altered in human breast cancer. Oncogene 2002, 21:4307-4316.
30. Ditsch N, Toth B, Himsl I, Lenhard M, Ochsenku¨hn R, Friese K, Mayr D, Jeschke U. Thyroid hormone receptor (TR)alpha and TRbeta expression in breast cancer. Histol Histopathol 2013, 28:227-237.
31. van de Vijver MV, Devilee P, Cornelisse C, Peterse J, Nusse R. Amplification of the neu(c-erbB-2) oncogene in human mammary tumors is relatively frequent and is often acccompanied by amplification of the linked c-erbA oncogene. Mol Cell Biol 1987, 7:2019-2023.
32. Moeller LC, Fu¨hrer D. Thyroid hormones, thyroid hormone receptors, and cancer: a clinical perspective. Endocr Relat Cancer 2013, 20:R19-R29.
33. Huang JBJG, Xing L, Jin LB, Xu CB, Xiong X, Li HY, Ren GS, Wu KN, Kong LQ. Implication from thyroid function decreasing during chemotherapy in breast cancer patients: chemosensitization role of triiodothyronine. BMC Cancer 2013, 13:334.